Slide 1: Danaher Corporation 2024 Overview
Danaher Corporation 2024 Overview Innovation at the speed of life.
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the fu
Slide 3: Danaher Today
Danaher Today Biotechnology ~$6.8B ~$24B 2024 Total Revenue Life Sciences ~$7.3B Biotechnolog Life y Sciences Diagnostics Diagnostics 28.6% ~$5.3B ~$9.8B Adjusted Free Cash Operating Profit Flow Margin Differentiated positioning, attractive end markets, improved financial profile All financial
Slide 4: Portfolio Transformation Into a Stronger, Better Danaher
Portfolio Transformation Into a Stronger, Better Danaher 1 Portfolio Market 2018 Acquisitions 2024 Exits Expansion ~$5B ~$1B >$1B EAS ~($7.6B) Dx Annual Revenue Cytiva 2024 Aldevron & Incremental Annual ~$20B Divested 2 Revenue Abcam 2024 Revenue Respiratory Revenue Dx ~$24B BT Dental Total Revenue
Slide 5: High-Quality Businesses in Attractive End Markets
High-Quality Businesses in Attractive End Markets Leading positions in attractive, fast-growing end markets United by a common business model • Long-term, strong secular growth drivers • Steady consumables stream off extensive • Regulatory requirements installed base • High value, ‘mission-critical’
Slide 6: Strong Secular Growth Drivers Central to Our Strategy
Strong Secular Growth Drivers Central to Our Strategy Proliferation of Advancements in Aging Global Shift in Medicine Adoption of New Monoclonal Life Science Population to Biologics Technologies Antibodies Research >1.5B >20K +DD 2.5X +10X Estimated number Biologics currently Monoclonal Increase in
Slide 7: Leading Bioprocessing Franchise
Leading Bioprocessing Franchise Cell Culture & SUT Chromatography Filtration Drug Product Cell expansion & Formulation Clarification Capture Viral inactivation Intermediate Polishing Viral filtration Bulk fill Drug product fill production & sterile filtration % of revenue Global mAb 2024 ~$6B Biopro
Slide 8: Well-Positioned in Life Sciences
Well-Positioned in Life Sciences Pharma & Strategic Clinical Biopharma • Differentiated positions in genomics, End-Market proteomics & analytical instrumentation Exposure Attractive Business • ~65% recurring revenue • Long-term margin expansion opportunities ~$7.3B Models 2024 Revenue Genomics • Acc
Slide 9: Portfolio Indexed to Highly Attractive Areas of Diagnostics
Portfolio Indexed to Highly Attractive Areas of Diagnostics Anticipated Long-Term Performance Leading molecular player with Cepheid Long- Best-in-Class Molecular Dx largest installed base & test menu DD Term Core Revenue Growth Scaled Scaled pathology and blood LBS & Radiometer Specialty Dx gas lead
Slide 10: Helping solve some of healthcare's biggest challenges
Helping solve some of healthcare’s biggest challenges Reducing Biologic Accelerating Drug Discovery Improving Patient Diagnoses Manufacturing Costs Cydem VT Automated Cell Culture System Sefia™ cell therapy manufacturing platform DxI 9000 Immunoassay Analyzer Helping reduce time to market by Address
Slide 11: Long-term Value Creation Through Strategic M&A
Long-term Value Creation Through Strategic M&A Market + Company + Valuation • Secular growth drivers • Competitive market position • Focus on ROIC • Fragmented • Strong brand / channel • DBS opportunities • Optionality across portfolio • Consistent revenue visibility • Synergies with DHR OpCos • Hig
Slide 12: How We Create Value: Running The Danaher Playbook
How We Create Value: Running The Danaher Playbook Improve cost Gross Core Revenue Growth structure Margins G&A + Margin Expansion + Reinvest R&D S&M Strong Free Cash Flow for growth + Acquisitions Accelerate Core = margins & Growth OMX core growth Top Quartile EPS Growth & Compounding Returns Balanc
Slide 13: The Danaher Business System (DBS)
The Danaher Business System (DBS) Kaizen is our way of life Customers talk, we listen DBS enables differentiated execution, at scale 13
Slide 14: 25 Year Total Shareholder Return: DHR vs S&P 500 and XLV
25 Year Total Shareholder Return: DHR vs S&P 500 and XLV 4000% S&P Healthcare Years DHR S&P 500 Index (XLV) 10 Year 319% 243% 137% 3000% 15 Year 867% 603% 471% 25 Year 2,958% 539% 547% 2000% 1000% 0% Dec-99 Dec-04 Dec-09 Dec-14 Dec-19 Dec-24 Outperforming over the long term Source: FactSet 14
Slide 15: Summary
Summary Differentiated positions in many of the most attractive areas of Biotechnology, Life Sciences and Diagnostics Portfolio transformation driving higher revenue growth, profit margin and cash flow profile Well-positioned to generate sustainable long-term shareholder value, driven by DBS 15
Slide 16: Segment Overviews
Segment Overviews 16
Slide 17: Biotechnology Overview
Biotechnology Overview ~$6.8B Bioprocessing Discovery & End Market Medical Revenue 2024 Revenue Global growth drivers N. America Recurring • Shift in medicine towards biologics W. Europe Non- recurring • Growth in biologics R&D pipeline HGM Geographic Revenue ROW • Increasing focus o
Slide 18: Life Sciences Overview
Life Sciences Overview Biopharma & ~$7.3B Pharma Applied End Market Genomics Revenue Rsrch. & Acad. 2024 Revenue Clinical Global growth drivers • Shift in medicine towards biologics N. America Recurring W. Europe Non- • Growth in biologics R&D pipeline recurring HGM Geographic Re
Slide 19: Diagnostics Overview
Diagnostics Overview Clinical ~$9.8B End Market Revenue Pathology & Acute/POC Molecular 2024 Revenue Global growth drivers • Penetration of molecular diagnostics N. America Recurring W. Europe Non- recurring • Point-of-care & decentralization of health Geographic HGM Revenue care R
Slide 20: »....
»....
Slide 21: Non-GAAP Reconciliations
Non-GAAP Reconciliations 21
Slide 22: Non-GAAP Reconciliations
Non-GAAP Reconciliations 22